Introduction {#sec1-1}
============

Renal artery stenosis (RAS) is a common peripheral vascular disease that may be present in 10%--40% of patients undergoing cardiac catheterization ([@ref1]). Its prevalence increases with aging, and it is particularly more common in those who have hypertension (HT) and renal failure ([@ref2], [@ref3]). Although ischemic stenosis of renal arteries is a relatively uncommon vascular disease, renal artery ischemia may overlap with other clinical syndromes. Despite the fact that various conditions may lead to RAS, atherosclerosis is the leading cause in many patients. Atherosclerosis typically affects relatively older people and those who present with HT and renal insufficiency ([@ref4]). In addition to the conventional risk factors, non-conventional risk factors, such as a low apolipoprotein A-1 level, high fibrinogen, high-sensitive C-reactive protein, and homocysteine levels, have been linked to RAS ([@ref5], [@ref6]).

It is known that platelets may be closely associated with inflammation ([@ref7]) and its role in onset, progression, and complications of atherosclerotic lesions has been demonstrated ([@ref7]). Mean platelet volume (MPV) is a potential marker of platelet reactivity, which has been shown by some previous studies to be one of the most important parameters of various systemic disorders ([@ref8]). Increased systemic platelet activation and MPV has been reported in various atherosclerotic diseases including carotid artery disease ([@ref9]) and transplant vasculopathy ([@ref10]) in addition to coronary artery disease (CAD) ([@ref11], [@ref12]). To the best of our knowledge, however, it is yet unclear if there is a relationship between RAS and MPV or other hematological parameters. The aim of our study was to investigate the relationship between the atherosclerotic renal artery stenosis (ARAS) and various hematological parameters including MPV in the first place.

Methods {#sec1-2}
=======

The patients and the demographic variables {#sec2-1}
------------------------------------------

This study was performed with a retrospective review of the angiographic images of 163 patients who underwent renal angiography for suspected uncontrolled HT, signs of secondary HT suggestive of ARAS, and severe HT during coronary angiography performed for a suspicion and/or signs of ischemic heart disease at catheter laboratory in Bülent Ecevit University, Faculty of Medicine, Department of Cardiology between January 2004 and December 2009. The exclusion criteria were as follows: acute coronary syndrome; hematological, oncological, or inflammatory disorder; white blood cell (WBC) count \>10400 mm^3^; hemoglobin level \<10 g/dL; history of a cardiac valve disease or a cardiac valve operation; using any anticoagulant drug; ejection fraction \<40%; renal insufficiency; liver or thyroid dysfunction; thrombocytopenia or thrombocytosis; and RAS not having the characteristics of an ARAS (as in the case of fibromuscular dysplasia). After exclusion of patients with the above mentioned exclusion criteria (3 patients with thrombocytopenia, 2 with a previous history of cancer, 10 with an elevated WBC count, 6 with thyroid dysfunction, 3 with fibromuscular dysplasia, 2 on anticoagulant therapy, 3 with anemia, 3 with acute coronary syndrome, and 3 with chronic renal failure) remaining 128 patients \[71 females (F) and 57 males (M); mean age 56.5±12.1 years\] were included in the study. All patients were hypertensive and 117 patients underwent coronary angiography while the remaining 11 did not.

Demographic characteristics were recorded, including diabetes mellitus (DM), HT, hyperlipidemia (HL), smoking history, and a family history of CAD. The following criteria were required to consider a patient hypertensive: having a history of HT; being on an antihypertensive therapy; or having a systolic blood pressure equal to or greater than 140 mm Hg and/or a diastolic blood pressure equal to or greater than 90 mm Hg, both of which were recorded after taking the mean value of two measurements from each arm. The criteria of being DM included having a previous history of diabetes and/or having a fasting glucose equal to or greater than 126 mg/dL. The patients were said to have HL when they had a fasting total cholesterol, low-density lipoprotein, and triglyceride level of ≥200 mg/dL, ≥160 mg/dL, and ≥200 mg/dL, respectively; and/or they were taking antihyperlipidemic agents. The family history of CAD was determined by the presence of a male first-degree relative younger than 55 years or a female first-degree relative younger than 65 years with a CAD history or sudden cardiac death.

Transthoracic echocardiography was performed with Vivid 5 echocardiography device (GE, Horten, Norway) using a 2.4 MHz phased array transducer. Simpson's rule was used to calculate left ventricular ejection fraction. The local ethics committee approved the study.

Analysis of the hematological parameters {#sec2-2}
----------------------------------------

Platelet indices were measured in blood samples drawn into collecting tubes containing tripotassium ethylenediaminetetraacetic acid (7.2 mg). All samples were analyzed by an automated blood counter (Beckman Coulter LH 780 Analyzer, Miami, FL, USA) within 1 h of collection.

Angiography {#sec2-3}
-----------

Coronary angiography (Integris BH 5000; Philips, Amsterdam, the Netherlands) was carried out with standard Judkin's technique using the femoral artery as the arterial entry point. The renal angiograms were obtained by injecting 20 cc contrast agent after the origin of each renal artery was seated with a pigtail catheter with multiple side holes. Coronary and renal angiograms were evaluated by two separate operators who were unaware of the clinical characteristics of the patients. The lesions causing coronary or renal artery stenosis above 50% were considered critical and below 50% were accepted as non-critical. Interobserver variability was within acceptable limits.

The patients were trichotomized into three groups based on the presence and severity of RAS. Group 1 included patients with a critical RAS (33 patients, 18 F, 15 M; mean age 61.6±11.5 years), group 2 comprised the patients with non-critical RAS (26 patients, 15 F, 11 M; mean age 58.1±11.3 years), and group 3 was composed of the patients without RAS (69 patients, 38 F, 31 M; mean age 53.5±11.9 years).

Statistical analysis {#sec2-4}
--------------------

All statistical analyses were performed using Statistical Package for the Social Sciences for Windows version 18.0 (Chicago, IL, USA). Shapiro--Wilk test was run to test if data met parametric test assumptions. Continuous variables were presented as mean ± standard deviation. One-way analysis of variance (ANOVA) was used for comparison of parametric variables and Kruskal--Wallis analysis of variance for non-parametric variables in three groups followed by a Tukey's HSD and Dunn's posthoc analysis. The difference between the two groups was analyzed with a two-sample unpaired t-test when parametric test assumptions were met. Categorical variables were compared with the chi-square test. Pearson's correlation analysis was performed to examine the relationship between continuous variables and outcomes. A p value less than 0.05 was considered statistically significant.

Results {#sec1-3}
=======

The mean age of group 1 was higher than that of the other groups ([Table 1](#T1){ref-type="table"}). The atherosclerotic risk factors of the groups were presented on [Table 1](#T1){ref-type="table"}. There were no significant differences between the groups with respect to the presence of atherosclerotic risk factors ([Table 1](#T1){ref-type="table"}). The medications used by the patients in different groups did not significantly differ ([Table 1](#T1){ref-type="table"}). Systolic blood pressure, diastolic blood pressure, and heart rate were significantly higher in group 1 than in groups 2 and 3 ([Table 1](#T1){ref-type="table"}).

###### 

Clinical characteristics of the groups

                         Group 1 (n=33)   Group 2 (n=26)   Group 3 (n=69)   *P*
  ---------------------- ---------------- ---------------- ---------------- -------
  Age, years             61.58±11.49      58.04±11.33      53.46±11.89      0.004
  Male, n                15               11               31               0.967
  Diabetes mellitus, n   10               4                16               0.405
  Family history of      7                5                10               0.669
  CAD, n                                                                    
  Hyperlipidemia, n      13               13               30               0.716
  Smoking, n             12               9                17               0.397
  Critical CAD, n        28               13               35               0.002
  Systolic BP, mm Hg     189.79±19.91     172.08±15.38     166.33±16.40     0.001
  Diastolic BP, mm Hg    106.03±11.66     100.42±8.41      98.78±7.28       0.001
  Heart rate, beat/min   87.88±10.26      85.20±7.26       81.85±10.61      0.016
  Drugs                                                                     
  b-blocker, n           16               12               22               0.340
  Ca antagonist, n       12               4                17               0.150
  ACE inhibitor, n       8                7                18               0.869
  ARB, n                 6                6                21               0.188
  Diuretics, n           8                11               27               0.120
  Antiplatelets, n       10               4                12               0.174
  Statin, n              8                7                13               0.648

ACE - angiotensin converting enzyme; ARB - angiotensin receptor blocker; BP - blood pressure; CAD - coronary artery disease

Comparison of the hematological variables revealed that MPV and platelet distribution width (PDW) were significantly higher in group 1 than in groups 2 and 3 (8.96±0.99 fL versus 8.35±0.76 fL, 8.31±0.79 fL, respectively; p=0.001; 16.53±0.58% versus 16.19±0.56%, 16.29±0.53%, respectively; p=0.04) ([Table 2](#T2){ref-type="table"}). Posthoc analyses demonstrated that group 1 and 2 differed from each other significantly with respect to both MPV and platelet distribution width (PDW), while groups 2 and 3 were not significantly different with respect to these parameters. WBC, red cell distribution width, and neutrophil/lymphocyte ratio were also significantly higher in group 1 than the other groups, albeit statistically non-significant. The rate of critical CAD was significantly higher in group 1 than in group 2. Correlation analyses revealed that there was significant but weak correlation between MPV, PDW values, and RAS percentage (r=0.23; p=0.008, r=0.26; p\<0.05, respectively). However, there was no correlation between MPV, PDW values, and RAS percentage when compared separately for groups 1 and 2.

###### 

Complete blood count parameters of the groups

                        Group 1 (n=33)   Group 2 (n=26)   Group 3 (n=69)   *P*
  --------------------- ---------------- ---------------- ---------------- -------
  WBC, x10^3^ mm^3^     8.02±1.33        7.47±1.35        7.73±1.50        0.330
  RBC, x10^6^ mm^3^     4.57±0.62        4.56±0.48        4.69±0.50        0.141
  HG, g/dL              13.44±1.60       13.38±1.65       13.77±1.67       0.473
  HCT, %                39.69±4.90       39.43±4.90       40.58±4.77       0.495
  MCH, picograms/cell   29.50±2.10       29.43±1.98       29.36±1.71       0.937
  MCV, fL               87.02±5.77       86.65±5.48       86.54±4.32       0.898
  MCHC, gr/dL           33.90±0.94       33.95±0.66       33.93±0.74       0.961
  RDW, %                13.41±0.97       13.38±1.21       13.09±0.87       0.212
  PLT, x10^3^ mm^-3^    255.00±73.97     248.31±53.07     262.10±46.45     0.542
  MPV, fL               8.96±0.99        8.35±0.76        8.31±0.79        0.001
  PCT, %                0.23±0.060       0.21±0.05        0.22±0.04        0.286
  PDW, %                16.53±0.58       16.19±0.56       16.29±0.53       0.042
  Lymphocyte, x10^3^    2.03±0.55        2.13±0.55        2.33±0.88        0.149
  mm^-3^                                                                   
  Neutrophi, x10^3^     5.11±1.17        4.52±1.17        4.59±1.31        0.101
  mm^-3^                                                                   
  Neutrophil/           2.73±1.14        2.27±0.91        2.27±1.23        0.144
  Lymphocyte ratio                                                         

HCT - hematocrit; HG - hemoglobin; MCH - mean corpuscular hemoglobin; MCHC - mean corpuscular hemoglobin concentration; MCV - mean corpuscular volume; MPV - mean platelet volume; PCT - plateletcrit; PDW - platelet distribution width; PLT - platelet count; RBC - red blood cell count; RDW - red cell distribution width; WBC - white blood cell count

Discussion {#sec1-4}
==========

The main findings of our study was that compared with the patients with normal renal arteries or non-critical ARAS, the patients with critical ARAS with multifactorial pathogens had higher MPV and PDW values, and MPV may contribute to ARAS pathogenesis in addition to conventional risk factors in this patient group.

RAS describes RAS limiting normal blood flow and it usually results from a heterogeneous group of factors including atherosclerosis (main factor), fibromuscular dysplasia, vasculitis, extrinsic compression, and radiation ([@ref13]). Majority of lesions are a result of atherosclerosis (ARAS) that typically involves the ostial and proximal 1/3 parts of the renal artery and usually has a close relationship with the aorta ([@ref14]). However, segmentary or diffuse intrarenal atherosclerosis may rarely be encountered. We also included stenoses, having the typical characteristics and radiological appearance of an atherosclerotic stenosis and excluded cases with characteristics consistent with fibromuscular dysplasia. Concomitant presence of ARAS and CAD doubles the mortality of patients. Although 90% of cases with ARAS have HT, it is still unclear whether HT is a cause or result of ARAS ([@ref15]). As any other atherosclerotic disease process, etiological factors for ARAS cannot be considered independent of conventional or novel risk factors. It is already known that the incidence of ARAS increases with aging ([@ref16]), DM ([@ref17]), smoking ([@ref18]), and strong family history ([@ref19]). In addition, an association between novel risk factors apolipoprotein A-1 ([@ref5]), fibrinogen, C-reactive protein, and homocysteine levels and ARAS has also been shown ([@ref6]). MPV is a relatively novel atherosclerotic risk factor that has increasingly drawn attention and many studies have been performed in recent years. Platelet volume has been demonstrated to have an association with other prognostic risk factors such as smoking, DM, obesity, and HT ([@ref20]). It has been shown that there is a strong link between platelets and inflammation, thrombosis, and atherogenesis. Platelets not only mediate vascular inflammation by releasing various cytokines and chemokines, but they can also be reactivated by substances released by cells attention deficit hyperactivity disorder vessel wall ([@ref21]). Platelets may attract leucocytes and progenitor cells to the vascular injury site and are capable of releasing pro-inflammatory, angiogenic factors and microparticles to circulation ([@ref22]). Furthermore, previous studies have shown that platelet factor 4 ([@ref14]) and other platelet-derived chemokines and growth factors are present in human atherosclerotic plaques ([@ref10], [@ref15]). Larger platelets contain more granules and hence exert greater hemostatic, vasomotor, and pro-inflammatory functions. Therefore, increased platelet activation is associated with larger platelet size ([@ref23]). We also found significantly higher MPV levels in patients with ARAS than in those without ARAS. MPV levels were significantly higher in patients with critical stenosis than in those with non-critical stenosis. Correlation analyses revealed a weak, but significant relationship between MPV and stenosis severity. These findings suggest that a higher MPV level is associated with ARAS.

Bath et al. ([@ref24]) investigated the platelet volume in two groups of patients at risk of a having ARAS with HT and peripheral vascular disease. They found increased platelet volume in patients with HT and angiographically proven atherosclerotic renal artery disease. They also found correlation between platelet volume and severity of renal artery disease in both groups. In our study, we found increased MPV and PDW values in patients with critical ARAS but not noncritical ARAS similar to that observed in the study of Bath et al. ([@ref24]). We found weak correlation between MPV values and stenosis severity. The limited number of cases may be the reason of this. We conclude that large platelets are hyperactive, increased platelet volume may contribute to the development of ARAS as stated by Bath et al. ([@ref24]).

Studies on MPV have pointed MPV as an independent risk factor for atherosclerosis, although its association with other risk factors is already known. Hypertensive patients have been reported to have higher MPV levels ([@ref25]). Similarly, smokers have been found to have higher MPV levels ([@ref26]), and hypercholesterolemia has been reported to affect platelet functions such as platelet size, aggregation, and activation ([@ref27]). In our study, all patients were hypertensive and nearly half of them had HL. Nearly all patients with ARAS have HT. Considering the close association between MPV and HT, we are of the opinion that MPV levels may play an important role in the pathogenesis of ARAS.

PDW is a parameter directly reflecting variability in platelet size ([@ref28]). The correlation between PDW values and acute coronary syndrome is debatable. Although there are some studies suggesting that it elevates in acute myocardial infarction and unstable angina ([@ref29]), some other studies have indicated that PDW is not be a risk factor for CAD ([@ref28]). Rosevear et al. ([@ref30]) reported higher PDW levels in gestational HT. We found higher PDW values in patients with ARAS than those without ARAS. We also showed a weak correlation between PDW values and blood pressure values and ARAS severity. This demonstrated that PDW values may be higher in patients with ARAS. We think that, with a possible contribution of high blood pressure, higher PDW levels are detectable in patients with ARAS.

Study limitations {#sec2-5}
-----------------

The main limitation of our study was its retrospective design. We could not ascertain which outcomes would be achieved by higher MPV levels in patients with ARAS because we did not follow our subjects in a prospective manner. One other limitation of our study was the assessment of atherosclerosis only by visual evaluation of angiographic images. An intravascular ultrasonography examination may have been more appropriate. However, the study center did not possess any intravascular ultrasonography device. One additional limitation of our study was the measurement of platelet count by only an automatic counter. Confirmation of platelet count and density by a peripheral smear may have been more reliable.

Conclusion {#sec1-5}
==========

In conclusion, MPV levels are higher in patients with ARAS. Considering both the effect of platelets on atherosclerosis and their close association with other risk factors, with HT being in the first place, MPV level may be an important factor in pathogenesis of ARAS.
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